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ABSTRACT

ROLE OF ETHANOL AS A COFACTOR IN HAART INDUCED
HEPATIC STEATOSIS AND INJURY
Hridgandh Donde
March 29, 2013

Highly Active Antiretroviral Therapy (HAART) has led to a significant
increase in the life expectancy of HIV patients; however, there are significant side
effects including lipodystrophy and hepatotoxicity. Alcohol abuse is highly
prevalent in HIV infected individuals and hence may be a significant negative
cofactor in HAART induced hepatotoxicity. The present study examines the
mechanisms underlying HAART and alcohol induced hepatotoxicity. The effects
of HAART drugs (azidothymidine, and Indinavir sulphate) in combination with
alcohol were examined in in vivo animal model.
Alcohol and HAART drug interactions and hepatotoxicity were also
assessed in-vivo using an animal model of chronic alcohol feeding. Mice were
pair-fed liquid diets (Lieber DeCarli) containing 35% of calories as alcohol
(alcohol-fed, AF) or as isocaloric maltose-dextrin (pair-fed, PF) for four weeks. In
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addition, HAART treatment groups received AZT (30mg/kg BW) and IDV
(50mg/kg BW) by oral gavage for 2 weeks. Animals exposed to both alcohol and
HAART developed increased visceral adiposity compared to pair-fed animal
suggesting disturbances in lipid metabolism in these mice. Lipodystrophy was
also evidenced by macro and microvesicular steatosis in the livers; elevated liver
triglycerides and free fatty acids. Additionally, animals receiving combinations of
alcohol and HAART exhibited increased inflammation and greater hepatic
neutrophil infiltration.
Overall, our data demonstrate that alcohol exacerbates HAART hepatotoxicity,
and is a significant cofactor in the development of hepatic steatosis and liver
injury.
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INTRODUCTION
HIV/AIDS- An overview
HIV (Human Immunodeficiency Virus) infection is one of the world's leading
infectious diseases, claiming more than 25 million lives over the past three
decades. HIV infection is considered pandemic by the World Health Organization
(WHO). Thirty four million people are affected worldwide. Center for Disease
Control (CDC) estimates 1.2 million people in the United States (US) are living
with HIV infection. One in five (20%) of those people are unaware of their
infection. By race, African Americans face the most severe HIV burden. Men
having sex with men (MSM), particularly the young, are most severely affected.
HIV leads to AIDS (Acquired Immunodeficiency Syndrome). AIDS was first
recognized in the United States in the summer of 1981, when the U.S. (CDC)
reported the unexplained occurrence of Pneumocystis jiroveci (formerly P. carinii)
pneumonia in five previously healthy homosexual men in Los Angeles [1].In
1983, human immunodeficiency virus (HIV) was isolated from a patient with
lymphadenopathy, and by 1984 it was demonstrated clearly to be the causative
agent of AIDS [1]. Since the epidemic began, an estimated 1,108,611 people in
the US have been diagnosed with AIDS [1]
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HIV & HAART
In order to prevent or delay resistance development, physicians are using a
regimen which consists of a combination of several types of antiretroviral drugs
that act on different sites on a retro virus and also target different stages in the
lifecycle of the virus. Such treatments are called highly active antiretroviral
therapy (HAART) [2] . The development of multi-drug combination therapy for
treatment of HIV disease is considered one of the great success stories of
modern medicine. In a period of approximately ten years, the death rate from HIV
disease was reduced by 50 to 80% [3]. Highly Active Antiretroviral Therapy
(HAART) as treatment for HIV infection has greatly improved mortality and
morbidity for adults and children living with HIV around the world [4, 5]. HAART is
the only treatment available to suppress the viral load. Currently used HAART
medication include Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
(Zidovudine, Didanosine, Abacavir), Non-nucleoside Reverse Transcriptase
Inhibitors (NNRT) (Nevirapine, Etravirine), Protease inhibitors (PI) (Indinavir or
IDV, Ritonavir, Lopinavir, Atazanavir), Fusion inhibitors (Enfuvirtide), Integrase
Inhibitors (Raltegravir), and CCR5 inhibitors all of which act on different sites on
HIV facilitating a decrease in viral load. Since the introduction of highly active
antiretroviral therapy (HAART) in the mid-1990s, the life expectancy of patients
with HIV has increased significantly [6, 7]. Although HAART has been widely
used in the treatment of HIV, HIV infected patients have experienced
complications associated with HAART, which cannot be ignored. Antiretroviral
toxicity, resistance, and adherence rank high on the list of problems that must be
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overcome if all, or at least the vast majorities, of HIV-infected patients are to gain
the long-term benefits associated with HAART [8]. Among these problems,
toxicity, real or perceived, is a major reason for patients either refusing or
prematurely discontinuing HAART [9].

The drop in mortality and morbidity due to opportunistic infection has been
accompanied by a concomitant increase in HAART-related hepatotoxicity which
caused discontinuation of HAART in increasing numbers of patients. HAART
hepatotoxicity, including lactic acidosis, hepatic steatosis and lipodystrophy,
occurs in approximately 10% of patients and is higher in those with underlying
liver disease [10].

Nucleoside Reverse Transcriptase Inhibotors (NRTI)- Nucleoside/nucleotide
reverse transcriptase inhibitors (NRTIs), which inhibit the formation of viral DNA
by incorporating into the newly formed DNA molecules, thereby preventing
further elongation of those molecules [2].
Zidovudine (AZT) - an important drug for 1st line therapy of HAART:
Zidovudine (AZT) (3'-azido-2'3'-dideoxythymidine) an analogue of thymidine, was
first discovered by Mitsuya and associates' to have antiretroviral activity. In 1986,
FDA approved this drug for the treatment of advanced HIV infection. Even today
it is widely being used in the resource limited settings as one of the important
drug for the 1st line therapy of HAART. However, it is now accepted that
prolonged use AZT leads to hepatotoxicity [11-13]. Mechanisms of hepatotoxicity
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induced AZT involves hepatomegaly or steatosis [14], elevated blood lactate to
pyruvate ratios, cytochrome c deficiency [11, 15-17]. Additionally, elevated liver
enzymes (AST, ALT) have been reported in patients receiving AZT therapy.
These hepatotoxic consequences are related only to AZT administration and are
independent of AIDS disease progression. This was confirmed when patients
administered with AZT therapy experienced one or more of these hepatotoxic
effects but when the therapy was discontinued the adverse effects were resolved
[18, 19]. These toxicities are mostly mediated through mitochondrial damage and
are associated with mitochondrial DNA depletion [17, 20]. Additional work is
required to identify molecular mechanisms to obtain a better understanding of
HAART/AZT induced hepatotoxicity and to develop therapeutic strategies. Hence
in the present study, we investigate the occurrence and mechanisms involved in
Zidovudine (AZT) induced hepatotoxicity in vivo in our well-established animal
model.

Protease Inhibitor (PI) - Protease inhibitors block the activity of the protease
enzyme, which HIV uses to degrade large polyproteins into the smaller pieces
required for assembly of new viral particles. All PIs are metabolized in the liver by
CYP3A isoenzymes; consequently their metabolic rates may be altered in the
presence of CYP inducers or inhibitors. Hence co-administration of PIs with
ritonavir (RTV), a potent CYP3A inhibitor will optimally increase PI exposure. Coadministration of PIs with a potent CYP3A inducer may lead to suboptimal drug
concentrations and reduced therapeutic effects of the PI [21]. While HIV can still
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replicate in the presence of protease inhibitors, the resulting virions are immature
and unable to infect new cells. PI –based regimen has seen demonstrated to
have anti-virologic potency. Unlike NRTI resistance, virologic failure rarely
selects for PI-resistance, which confers it with increased efficiency in decreasing
the viral load.

Indivavir- A commonly used Protease inhibitor in resource limited setting:
In 1996 Indinavir was approved as one of the PIs by the FDA, which dramatically
modified the clinical management of HIV-1. IDV is a synthetic peptidomimetic
competitive inhibitor of the HIV aspartyl protease, which is involved in the
cleavage of the gag and pol gene products into their functional components and,
as a consequence, viral particles are unable to undergo final maturation into
infectious virions. A number of metabolic abnormalities, including
hypertriglyceridemia, hypercholesterolemia, hyperinsulinaemia and lipodystrophy
increase in liver enzymes have been associated with PI use [21-23]. Thus along
with the efficacious nature of PI based therapy, recent studies have revealed
several adverse effects leading to discontinuation of the therapy causing the viral
load to increase. Hence this demands a need to investigate the underlying
molecular mechanisms that could provide potential therapeutic interventions.
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HAART associated hepatotoxicity and liver injury
HAART causes a variety of adverse effects like cardiovascular diseases,
neurological disorders, Liver disease, lipodystrophy, non-Hodgkin lymphoma to
name a few. Liver disease is recognized as an increasingly important problem for
the HIV population, and may be due to a variety of factors including co-infection
with viral hepatitis, alcohol abuse, and antiretroviral hepatotoxicity. Liver disease
is now a leading cause of death for patients with HIV. In patients coinfected with HIV and hepatitis C, cirrhosis was the underlying cause of
death in nearly 50% [9]. In a more general HIV population, liver disease was
the second most common non-HIV-related cause of death, trailing only
cancer [24]. In a recent American study, which evaluated the causes of death of
HIV-infected individuals, discontinuation of ART due to hepatotoxicity increased
from 6% in 1996 to 31.8% in 1998-1999 among those mortalities [25]. The
severity of liver toxicity ranges from the absence of symptoms to liver
decompensation, and the reported incidence of severe liver toxicity after initiating
HAART ranges from 2% to 18%. Hepatotoxicity due to HAART is also common
and up to 30% of patients on HAART experience World Health Organization
grade 3 liver enzyme elevations. Hepatotoxicity induced by these agents has
been identified on the basis of circulating liver enzymes (ALT, AST, and GGT) in
association with increased lactate levels. In more dramatic situations, liver failure
has occurred leading to discontinuation of treatment. The study of hepatotoxicity
induced by HAART is complicated by the diverse chemical nature of the agents
and by the differences between the effects of agents used singly or in
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combination. Hepatotoxicity from antiretroviral drugs has led to adverse patient
outcomes either from fulminant hepatic failure, or more commonly, AIDS
following discontinuation of HAART. Hence, it is highly relevant to study the
underlying mechanisms of HAART-induced hepatotoxicity.
HAAART-induced dyslipidemia and liver lipid metabolism
It has been recently found in long-term and short-term studies that on healthy as
well as HIV infected patients, HAART regimen particularly protease inhibitors
induces dyslipidemia [23, 26-28]. Often Clinicians supplement these drugs with
lipid lowering drugs.
Since liver is the first organ to come in contact with the administered
HAART, liver is the key organ in handling multiple downstream processes and
their metabolites. Hepatocytes are involved in lipid homeostasis and the
metabolism of drugs. Endoplasmic reticulum (ER) plays a key role in regulating
hepatic lipid metabolism. The ER is a critical organelle responsible for proper
protein folding, cellular calcium levels, lipid synthesis and the secretory pathway.
Thus ER stress is induced via depletion of ER calcium stores, changes in ER
lipid membrane composition or accumulation of misfolded protein.
Moreover, sterol regulatory element-binding proteins (SREBPs) are
transcription factors that are present on ER membrane. The isoforms of SPEBP
(SREBP-1c and SREBP-2) play a major role in regulating the expression of key
genes such as 3-hydroxy-3-methlgutaryl-CoA (HMG-CoA) synthase, Fatty acid
synthase (FAS), acetyl-CoA carboxylase (ACC) involved in lipid metabolism. ER
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stress via altering lipid metabolism could be a potential mechanism of PI-induced
dyslipidemia and deregulation of hepatic lipid metabolism.
Alcohol as a cofactor in HAART (AZT and IDV) induced Hepatotoxicity
As per National Epidemiologic Survey on Alcohol and Related Conditions
(NESARC) an estimated 136 million adults consume alcohol in the United States,
and an estimated 14 million Americans are alcoholics[29]. Alcoholic liver disease
accounts for 40% of deaths due to cirrhosis and more than 30% of hepatocellular
carcinoma. Alcohol abuse and HIV are important health problems. Alcohol use is
common in the HIV population. It is estimated that approximately 25% of recently
diagnosed HIV patients also developed alcohol addiction, which has been
associated with HIV treatment failure [30]. Studies have shown that alcohol
abuse is associated with more severe hepatotoxicity in patients on HAART [31].
Importantly, alcoholic liver disease and HAART induced liver injury share many
potential mechanisms of injury. These include cytokine dysregulation,
mitochondrial dysfunction, and proteasomal dysfunction. Through these and
other mechanisms, alcohol and antiretroviral medications converge on the liver in
an overlapping fashion to produce hepatotoxicity. Alcohol abuse can cause a
variety of metabolic abnormalities including induction of CYP2E1, mitochondrial
dysfunction, oxidative stress, depressed hepatic proteasome function, hepatic
steatosis, and in some instances more advanced liver disease with chronic
abuse [32-34]. Alcohol abuse also can increase susceptibility to certain types of
drug-induced liver injury (e.g., acetaminophen) and accelerate the progression of
chronic liver disease such as HCV [8, 33, 35]. Additionally, Zidovudine and
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indinavir as mentioned previously has been reported to develop severe hepatic
steatosis, elevated liver enzymes and hepatotoxicity. Since alcohol and HAART
drugs (AZT, IDV) have similar hepatotoxic effects on liver, we propose that the
combination would exacerbate these effects. Hence in this study we are studying
the combinatorial effects of alcohol and HAART (AZT, IDV) on liver that would
pinpoint some therapeutic interventions. Besides liver, alcohol abuse also has an
adverse impact on other organ systems particularly the gut, liver and the immune
system. Work done by our research group and others has shown that chronic
alcohol exposure leads to intestinal oxidative stress, epithelial barrier disruption
and enhancement of gut leakiness and consequent endotoxemia and systemic
inflammatory response [36].
Gut-Derived Endotoxemia and Alcohol-induced liver injury:
Due to its anatomical links to the gut, the liver is constantly exposed to gutderived bacterial products, and functions as a major filter organ and a first line of
defense. Gut-derived endotoxin is a crucial mediator of liver injury in alcoholic
liver disease. This is demonstrated by the significant reduction of alcoholic liver
injury following elimination of the Gram-negative microbiota by antibiotics [37]
and the sensitization to LPS-induced liver injury following long-term ethanol
exposure [38]. The elevation of endotoxin appears to be predominantly caused
by two mechanisms. First, alcohol consumption leads to changes in the intestinal
microbiota; and upper gastrointestinal tract bacterial overgrowth is more than six
times more frequent in people who are very heavy drinkers than in people who
do not drink heavily [39, 40]. However, the effects of alcohol on the composition
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of the intestinal microbiota have not been studied in detail. Second, a large body
of literature has clearly documented that alcohol ingestion disrupts the intestinal
epithelial barrier causing enhanced permeability [41-43] thus allowing increased
amounts of LPS to enter the portal circulation. Moreover, it has been suggested
that the intestinal microbiota converts ethanol into acetaldehyde, which in turn
disrupts tight junctions and increases paracellular permeability [44, 45]. On the
other hand, not much is known about the effects of HAART drugs per se on
systemic endotoxin or Lipopolysaccharide (LPS). Most of the clinical trial studies
focus on HIV-1 infection and the increase systemic endotoxin. Hence more
studies are required to tease out the effects of HAART on endotoxin levels and
its subsequent hepatic consequences. In order to address this issue we are
interested in finding the effects of HAART on systemic endotoxin in vivo.
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SIGNIFICANCE AND CLINICAL RELEVANCE
In the United States, approximately 2000 cases of acute liver failure occur
annually and drugs account for over 50% of them (39% are due to
acetaminophen, 13% are idiosyncratic reactions due to other medications).
Drugs account for 2-5% of cases of patients hospitalized with jaundice and
approximately 10% of all cases of acute hepatitis. HAART has been associated
with increase in morbidity and mortality due to HAART-related hepatotoxicity and
finally discontinuation of therapy. This is especially true in patients who are coinfected or have other cofactors such as alcohol abuse. The mechanisms for
HAART hepatotoxicity in association with alcohol consumption or other cofactors
have received very limited attention. There is no well-accepted therapeutic
intervention except for abstinence and HAART discontinuation. Recent work
indicates that the liver is an important target for alcohol-induced damage and is
often associated with gut-generated signals. Findings from this project could
provide important mechanisms by which alcohol/HAART-induced pathology in
the gut influences the liver inflammatory responses often observed in alcohol
abuse. Moreover, the findings from this study would be significant in the
development of successful preventive and therapeutic strategies in most-at-risk
populations. Finally, the proposed studies will focus on direct hepatotoxicity due
to HAART and alcohol as a co-factor by the combinations of Zidovudine and
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Indinavir (HAART drugs), defining the disease mechanisms and generate
therapeutic targets.
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MATERIALS AND METHODS
Reagents
Zidovudine (AZT) and Indinavir (IDV) were purchased from Sigma-Aldrich (St.
Louis, MO). Chloroacetate Esterase Staining reagents were also obtained from
Sigma-Aldrich (St. Louis, MO). TRIzol® was obtained from Invitrogen (Carlsbad,
CA). Triglycerides and ALT (Alanine Aminotransferase) reagents were obtained
from Thermo Fisher Scientific Inc. Reagents for Free Fatty acids were obtained
from Wako Chemical USA (Richmond, VA, USA); Endotoxin reagents were
obtained from with Limulus Amebocyte Lysate kit (Lonza, Walkersville, MD).
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Animal Model
Eight-week-old male C57BL⁄6N mice were obtained from Harlan (Indianapolis,
IN). All mice were housed in a pathogen-free, temperature-controlled animal
facility accredited by the Association for Assessment and Accreditation of
Laboratory Animal Care with 12- hour light ⁄ 12 hour dark cycles. All experiments
were carried out according to the criteria outlined in the Guide for Care and Use
of Laboratory Animals and with approval of the University of Louisville Animal
Care and Use Committee.
Animals were fed a modified Lieber–DeCarli liquid diet containing Ethanol (EtOH)
(35% of total calories) and enriched in Unsaturated Fatty Acid (USF) (corn oil);
Research Diet, New Brunswick, NJ. Control liquid maltose-dextrin diets provided
40% of energy from fat, 43% from carbohydrate, and 17% from protein. Initially,
all mice were given the control liquid maltose dextrin diets (USF, no EtOH) ad
libitum for 1 week. Afterward, mice were fed either the liquid EtOH diet or the
control liquid maltose-dextrin diet. EtOH was gradually increased every 3 to 4
days from 11.2 to 35% of total calories [(5.0%(v⁄v)]. The mice were fed the
Ethanol diet [5% (v⁄v)] ad libitum for 4 weeks. The control mice were pair-fed USF
maltose-dextrin diets on an isocaloric basis. For HAART therapy, (AZT 30mg/kg)
and (IDV 50mg/kg) were gavaged every day for last 2 weeks to animals
administered alcohol or pair-fed (control) diet.
At the end of the feeding experiment, mice were anesthetized with sodiumpentobarbital (nembutal, 80 mg ⁄ kg, intraperitonially), and blood and liver were
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collected for assays. The killing sequence was randomized to eliminate any timedependent variation due to length of fasting. Blood samples were collected from
the inferior vena cava using heparinized syringes and were then centrifuged at
7000·g for 7 minutes at 4°C. Whole liver were removed. Part of the liver from left
lobe was harvested and fixed in 10% neutral- buffered formalin, while the
remaining liver tissue was snap frozen in liquid N2 and stored at 80°C.
Hematoxin and Eosin staining
Staining was performed using Hemo-De or Citrosol. Staining was done in a
Copland jar with a stir bar at the bottom of the jar. All slides should be stained
with hematoxylin and eosin, respectively. Consequently the slides were kept in
Hemo-De for 10mins, 100% EtOH for 10mins, 95% EtOH for 10mins, 85% EtOH
for 10mins, 70% EtOH for 10mins and 30% Etoh for 10mins followed by
Hematoxylin soln for 1-3mins.
Liver Histological Examination
For histological analysis, liver sections were fixed in 10% buffered formalin for 24
hours and embedded in paraffin. Tissue sections were stained with hematoxylineosin and examined under light microscopy at 200· magnification.
Oil Red O staining
Frozen liver sections were washed in phosphate buffered saline twice for 5
minutes. Oil-Red-O and 85% propylene glycol were added with agitation for 15
minutes, followed by washing in tap water.
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Chloroacetate Esterase Stain
Neutrophil accumulation was assessed by localizing chloracetate esterase
(CAE), a specific marker for neutrophils, in liver tissue by using the naphthol ASD chloracetate esterase kit (Sigma)
ALT assay
Alanine aminotransferase (ALT) activity was measured as a marker of liver injury
using commercially available reagents from Thermo Fisher Scientific Inc.
(Middletown, VA).
Liver Triglycerides Assay
For liver TAG assay, hepatic tissue (100 mg) was homogenized in 50 mM NaCl.
The homogenate (500 μl) was mixed with chloroform/methanol (2:1, 4 ml) and
incubated overnight at room temperature with gentle shaking. Homogenates
were vortexed and centrifuged for 5 min at 3000Å~g. The lower lipid phase was
collected and concentrated by vacuum. The lipid pellets were dissolved in 1%
Triton X100 in phosphate-buffered saline, and hepatic TAG content was
determined via enzymatic colorimetric methods.
Hepatic Free Fatty Acids
Liver nonesterified-fatty acid (NEFA) were assayed using a commercially
available kit fromWako Chemical USA (Richmond,VA).
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Blood Endotoxin Assay
Plasma endotoxin levels were measured with Limulus Amebocyte Lysate kit
(Lonza, Walkersville, MD) according to the manufacturer’s instructions.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism version 5.01 for
Windows (GraphPad Software, Inc., La Jolla, CA). One-way analysis of variance
(ANOVA) followed by Tukey’s post hoc test was used to evaluate significant
differences between the 4 compared groups (Pair-Fed Controls+ EtOH, HAART
drugs, EtOH+HAART drugs). A p-value of <0.05 was considered statistically
significant. Data were expressed as mean ± SEM.

17

RESULTS

HAART drugs in combination with alcohol increases visceral fat
accumulation in mice in comparison with HAART or alcohol-fed groups
Lipodystrophy is one of the common features of long-term HAART therapy
commonly seen in HIV-1 infected patients. This is associated with a loss in
peripheral fat and an increase in visceral fat accumulation [46, 47]. However,
whether alcohol consumption along with HAART drugs would further enhance
HAART induced lipodystrophy still remains unclear. Hence, we visually examined
the visceral fat accumulation in our experimental groups. Our data suggests that
the combination group (Alcohol+HAART) had a significant amount of visceral fat
accumulation in comparison with the mice gavaged HAART drugs and/or alcoholfed groups showing an additive effect of drugs and alcohol. This could be possibly
due to decrease in the amount of lipolysis in the adipocytes as well as in the
hepatocytes or increased lipogenesis in mice receiving HAART and alcohol (fig.
1).
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Figure 1: Administration of HAART drugs and alcohol leads to increased
visceral fat accumulation
Pictorial representation of mice from different groups such as HAART drugs and
alcohol (alcohol+ AZT+IDV), HAART drugs (AZT+IDV), alcohol and pair-fed
(controls) showing visceral fat accumulation the most in HAART drugs and
alcohol group (alcohol+ AZT+IDV)
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Administration of HAART drugs and alcohol enhances alcohol induced
Micro- and Macro-Vesicular Steatosis
Since we reported increased visceral fat accumulation in (alcohol+AZT+IDV)
group (fig. 1) we were interested in examining the fat deposition (steatosis) in the
whole liver. We examined the effect of HAART and alcohol on the whole liver by
Hematoxylin and Eosin (H&E) staining and Oil Red O staining. Alcohol further
worsened HAART induced steatosis. Indeed, we confirm the development of
both micro- and macro vesicular steatosis in (alcohol+AZT+IDV) group (fig. 2).
This data suggests that HAART drugs in combination with Alcohol could
potentially exacerbate hepatic steatosis in comparison with HAART drugs or
alcohol administered mice.

20

Figure 2: H&E staining of liver tissue
H&E staining of hepatic sections established the presence of micro-vesicular
steatosis in alcohol and the (Alcohol+AZT+IDV) fed groups.
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Figure 3: Oil Red O Staining of liver tissue
Oil Red O staining of hepatic sections established the presence of macrovesicular steatosis in alcohol and the (Alcohol+AZT+IDV) fed groups.

22

Administration of HAART drugs and alcohol significantly increases hepatic
triglycerides whereas hepatic free Fatty acids levels remained unchanged
in (alcohol+AZT+IDV) and AZT+IDV groups in comparision with alcohol and
controls group
In the liver, glycerol combines with fatty acids to form triglycerides as a byproduct
of digestion of fats. Triglycerides play a very important role in digestion and
metabolism by acting as transporters of dietary fats. The presence of fatty livers
results mainly from the accumulation of triacylglycerols. Moreover free fatty acids
are a key mediator of lipotoxicity in the liver. Increase in triglycerides and free
fatty acids in the liver could potentially lead to lipodystrophy and dyslipidemia.
Hepatic fat accumulation (fig.2, 3) was further confirmed by increase in the
hepatic triglycerides. Hepatic triglycerides and free fatty acids were quantified
biochemically.
In (AZT+IDV) group hepatic triglycerides were significantly higher than pair-fed
(controls). Additionally, hepatic triglycerides in (alcohol+AZT+IDV) were
significantly high than (AZT+IDV) or control groups. On the contrary, there was
no significant difference in the free fatty acids in the above mentioned groups.
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Figure 4: Effects of HAART (AZT+IDV) and alcohol singly and in
combination on hepatic triglycerides and free fatty acids (FFA)
Hepatic triglycerides were quantified as (mg/g liver) in mice whereas Free fatty
acids (FFA) was measured in (mEq/L) in mice fed with alcohol, (AZT+IDV),
(Alcohol+AZT+IDV) and pair-fed (control). (Alcohol+AZT+IDV) significantly
increased hepatic triglyceride levels compared to pair-fed (control), (AZT+IDV)
whereas FFA levels remained unchanged. Data is presented as mean ± SEM,
n=5 animals/group; * p<0.05 when compared to controls. Anova was used to
evaluate significant differences between the 4 different groups
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Administration of HAART drugs and alcohol causes increased serum
endotoxin levels in mice.
Work done by our research group and others has shown that chronic alcohol
exposure leads to intestinal oxidative stress, epithelial barrier disruption and
enhancement of gut leakiness and consequent endotoxemia and systemic
inflammatory response [36]. Acute and chronic ingestion of alcohol lead to a
significant elevation of portal and systemic levels of endotoxin in animal models
and humans[48-50]. In our experimental groups we reported significantly higher
serum endotoxin levels specifically in (alcohol+AZT+IDV) fed mice as compared
to (AZT+IDV) and pair-fed (control) groups (fig. 5).
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Figure 5: Effects of HAART drugs (AZT+IDV) and alcohol singly and in
combination on serum endotoxin
Serum endotoxin levels were quantified as (EU/ml) in mice fed with alcohol,
(AZT+IDV), (Alcohol+AZT+IDV) and pair-fed (control). (Alcohol+AZT+IDV)
significantly increased systemic endotoxin levels as compared to (AZT+IDV) and
pair-fed(control). Data is presented as mean ± SEM, n=5 animals/group;
* p<0.05.
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Administration of HAART drugs and alcohol leads to an increase in
neutrophil infiltration (Inflammation)

Neutrophils accumulate within the hepatic microvasculature, which
includes sinusoids and in postsinusoidal venules. A variety of inflammatory
mediators such as TNF-α, IL-1, CXC chemokines [(e.g., IL-8, Macrophage
inflammatory protein-2 (MIP-2), keratinocyte-derived chemokine (KC), cytokineinduced neutrophil chemoattractant-1 (CINC-1)], and platelet activating factor
(PAF)), can cause neutrophil infiltration within the hepatocytes [51-55]. It is well
known that alcohol consumption in humans results in neutrophilic steatohepatitis
[56-58]. Neutrophil infiltration in the liver is known to significantly contribute to the
pathologic findings noted in alcoholic liver injury (ALI) [56, 57, 59].
In order to evaluate the Neutrophils accumulation we performed
Chloroacetate Esterase (C&E) Staining procedure in the whole liver. We
confirmed increased levels of neutrophils in HAART and alcohol administered
mice livers as compared to individual groups.
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Figure 6: CAE staining of liver tissue
CAE staining of hepatic sections established the presence of neutrophil
recruitment in (Alcohol+AZT+IDV) mice group
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Administration of HAART drugs and alcohol lead to an increase in serum
ALT levels
Serum alanine aminotransferase (ALT) levels are the hallmark of liver injury. It
has been well documented that chronic alcohol consumption leads to elevated
ALT levels in the blood indicating liver injury. In the present study, ALT levels
were significantly elevated in Alcohol and in (alcohol+AZT+IDV) groups in
comparison with pair-fed (Control). Although, ALT levels in (alcohol+AZT+IDV)
were not significantly higher than alcohol group.
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Figure 7: Effects of HAART (AZT+IDV) and alcohol on serum ALT levels
Serum ALT levels (U/L) were measured using ALT reagent from Thermo
Scientific as per manufacturer’s instructions. Chronic alcohol & HAART
(alcohol+AZT+IDV) administration resulted in significant increase in the serum
ALT levels in comparison with pair-fed (control) , and AZT+IDV fed mice. Data is
presented as mean ± SEM, n=5 animals/group; * p<0.05. Anova was used to
evaluate significant differences between the above mentioned groups.
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DISCUSSION
In this study, we tested the combinatorial the effects of HIV medication
HAART specifically a combination of NRTI and PI with chronic alcohol
consumption on hepatic injury in animals. Chronic alcohol consumption (4
weeks) lead to a fulminant steatohepatitis and moderate dyslipidemia that is
consistent with other well documented studies. Administration of HAART drugs
further increased the hepatotoxic consequence of alcohol.
In our results, combination of HAART and alcohol resulted in a synergistic
increase in visceral fat accumulation already seen in the group of animals on
HAART drugs. It is well-documented that visceral-fat accumulation is associated
with the use of PIs like Indinavir [60]. This data clearly suggests that there is a
possibility of dysregulation in the body fat redistribution and potential
lipodystrophy in animals receiving HAART and alcohol. Consequently, we
confirmed that micro- and macro- vesicular steatosis was significantly increased
in animals receiving HAART and alcohol as compared animals administered
HAART or alcohol alone. This further established the occurrence of dyslipidemia
in these animals.
It has been shown in humans as well as animals that chronic alcohol
consumption leads to the development of fatty liver [61]. This incidence of fatty
liver is due to the accumulation of triacylglycerols. Since we confirmed the
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occurrence of macro- and micro- vesicular steatosis in the whole livers of these
mice we analyzed the lipid profile specifically hepatic triglycerides and free fatty
acids. As expected, we reported marked increase in the hepatic triglycerides in
animals receiving alcohol as well as HAART in comparison with HAART or
alcohol and pair-fed controls.
Work done by our research group and others has shown that chronic
alcohol exposure leads to intestinal oxidative stress, epithelial barrier disruption
and enhancement of gut leakiness and consequent endotoxemia and systemic
inflammatory response. Moreover, alcohol consumption affects both aerobic and
non-aerobic intestinal bacteria resulting in altered gut bacterial composition
(dysbiosis). Additionally, alcohol induced endotoxemia is also influenced by
depressed hepatic clearance of circulating endotoxin shown in both acute and
chronic alcohol consumption causing intestinal barrier dysfunction. Moreover,
there are no clinical reports or literature on the effect of HAART drugs per se
(without any viral load) on systemic endotoxin. In this regards, we report a
significant increase in the circulating systemic endotoxemia in animals on
HAART and alcohol administration when compared with HAART or alcohol group
animals alone. Serum Aminotransferase activity, which is an indicator of liver
injury also followed the same tread of being significantly higher in in animals
receiving HAART and alcohol together.
Overall, our data suggests that the combination of alcohol and HAART
(AZT & IDV) would have detrimental on liver. Hence the mechanisms underlying
the liver toxicity due to HAART and alcohol need further investigation which
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would lead to potential therapeutic targets. These pharmacological interventions
could be supplemented with HAART drugs that would help in continuation of the
therapy without any hepatotoxic effects.
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SUMMARY
The highly Active Anti-Retroviral therapy has been shown to improve the life
expectancy of HIV-1 patients during the last two decades [6, 9]. It is now clear
that alcohol abuse can alter/suppress immune function, including CD4 Tlymphocyte depletion, which can accelerate HIV progression. Subjects who
consume alcohol may be more likely to develop certain infectious diseases that
can complicate HIV, examples being various types of pneumonia and
tuberculosis. Patients who consume alcohol also may be less compliant with their
HIV therapy, which can affect disease progression. Moreover, Liver disease is
now a leading cause of death for patients with HIV. Liver disease may be due to
a variety of factors including co-infection with viral hepatitis, alcohol abuse, and
antiretroviral hepatotoxicity. Hence in this preliminary animal study we are
shedding some light on the mechanisms of alcohol and HAART mediated hepatic
steatosis, inflammation and injury.
Our data suggests that HAART medication along with a cofactor like alcohol
causes an increase in micro- and macro-vesicular steatosis leading to an
increase in hepatic triglycerides possibly leading to dyslipidemia. Neutrophil
infiltration (inflammation) was clearly increased in animals receiving HAART and
alcohol. Serum endotoxemia was significantly more in animals receiving HAART
drugs along with alcohol indicating intestinal barrier dysfunction. We also
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reported liver injury in the form of increased serum aminotransferase activity in
animals on HAART and alcohol. In conclusion, alcohol/HAART combination
causes severe hepatotoxic consequences. Further investigations are required to
understand the underlying mechanisms leading to potential targets for
therapeutic interventions.
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